Loading…
Indian pharmaceutical company making active pharmaceutical ingredients (APIs), generic formulations and contract manufacturing (CDMO) services, notably in antiretroviral (HIV) drugs.
Indian pharmaceutical company making active pharmaceutical ingredients (APIs), generic formulations and contract manufacturing (CDMO) services, notably in antiretroviral (HIV) drugs.
Sells active ingredients and finished tablets for HIV treatment to generic makers and to donor-funded global health programs, usually through tenders where price decides the award. It has added contract manufacturing for drugmakers and a biotech unit, Laurus Bio, to reduce reliance on those drugs. Founder Satyanarayana Chava is the largest shareholder.
In one line: India's smaller API-focused CDMO, like a slice of Lonza.
Moat: narrow (process know-how, scale, regulatory licence). Deep manufacturing scale and regulatory approvals in antiretroviral APIs make it a key supplier to global HIV treatment programs.
Headquarters: Hyderabad, India · Founded: 2005 · Employees: 13,832
Size Laurus Labs (LAURUSLABS.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $13.3B, the 80th largest of 1,058 India companies the cockpit tracks. Shares closed at ₹2,340 on 6 Nov 2026.
Performance Over six months the shares gained 94.0%, against +4.5% for the median peer and 0.0% for the India market (cap-weighted) — 2nd highest of 21 in its peer set.
Growth Revenue grew 23.0% over the last twelve months (peer median +14.5%); the operating margin is 24.1% (peer median 19.6%).
Valuation It trades at 77.0× forward earnings against a peer median of 24.5× (2nd most expensive of 19).
Price implies For today's price to make sense, revenue must grow about 51% a year for seven years (Req g). Recent delivered growth is +7%, so the hurdle is +44 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 2.0 points above its cost of capital (14.1% WACC).
Next results Next results expected around 28 Jan 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹78.2B | ₹68.1B | ₹55.5B | ₹50.4B | ₹60.4B |
| Revenue growth | — | +23% | +10% | -17% | — |
| Gross profit | ₹33.7B | ₹18.4B | ₹10.8B | ₹7.21B | ₹15.9B |
| EBITDA | ₹23.8B | ₹18.0B | ₹10.8B | ₹8.04B | ₹16.4B |
| Net income | ₹13.4B | ₹8.89B | ₹3.58B | ₹1.61B | ₹7.90B |
| Free cash flow | n/a | ₹3.89B | -₹2.42B | -₹1.81B | -₹1.32B |
| Capital expenditure | n/a | ₹10.7B | ₹6.41B | ₹6.78B | ₹9.90B |
| Total debt | ₹26.3B | ₹25.2B | ₹27.6B | ₹25.8B | ₹20.2B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Laurus Labs LAURUSLABS.NS | $13.3B | +94% | +23% | 24% | 77.0× | 50.9% |
| Anthem Biosciences ANTHEM.NS | $5.46B | +17% | -1% | 35% | 69.9× | 36.7% |
| Divi's Laboratories DIVISLAB.NS | $29.0B | +54% | +16% | 31% | 82.0× | 50.9% |
| Aurobindo Pharma AUROPHARMA.NS | $10.9B | +22% | +14% | 15% | 22.4× | 21.0% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | LAURUSLABS.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +14.0% | +7.3% | 8th highest of 21 |
| 6-month return | +94.0% | +4.5% | 2nd highest of 21 |
| Distance from 52-week high | -4.2% | -10.4% | 6th highest of 21 |
| Revenue growth (TTM) | +23.0% | +14.5% | 9th highest of 21 |
| Operating margin | 24.1% | 19.6% | 10th highest of 21 |
| Forward P/E | 77.0× | 24.5× | 2nd most expensive of 19 |
| Growth the price implies (Req g, 7 yrs) | 50.9% | 0.7% | 3rd most demanding of 17 |
| Growth delivered (Del g) | +7.3% | +12.6% | 5th lowest of 17 |
| Hurdle (Req g minus delivered) | +43.6 pp | -11.2 pp | most demanding of 17 |
| ROIC minus cost of capital | +2.0 pp | +1.4 pp | 10th highest of 21 |
| EV / EBITDA | 53.8× | 15.7× | 3rd most expensive of 14 |
| Net debt / EBITDA | 1.1× | -0.1× | 6th most indebted of 15 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Laurus Labs LAURUSLABS.NS | India | $13.3B | +94% | +23% | 24% | 77.0× | 50.9% | +7.3% |
| Sichuan Kelun-Biotech Biopharmaceutical 6990.HK | Hong Kong | $13.9B | 0% | +44% | -38% | 1,255.9× | 56.2% | +33.7% |
| Sbp 1177.HK | Hong Kong | $12.7B | +4% | +15% | 30% | 18.3× | -5.4% | +5.4% |
| Zydus Lifesciences ZYDUSLIFE.NS | India | $12.7B | +27% | +24% | 17% | 29.8× | n/a | n/a |
| Recordati REC.MI | Italy | $12.3B | +3% | +9% | 30% | 16.7× | 1.9% | +12.6% |
| Zhangzhou Pientzehuang Pharmaceutical 600436.SS | China | $12.3B | -5% | -19% | 19% | 42.1× | 25.8% | +6.8% |
| Dr. Reddy's Laboratories DRREDDY.NS | India | $12.1B | +5% | -4% | 9% | 31.8× | 30.1% | +12.1% |
| Yunnan Baiyao 000538.SZ | China | $14.7B | +4% | +5% | 11% | 18.0× | -0.5% | +4.7% |
| Ipsen IPN.PA | France | $14.7B | -4% | +14% | 30% | 10.9× | -7.3% | +7.2% |
| Jazz Pharmaceuticals Public JAZZ | United States | $15.1B | +4% | +13% | 25% | 8.9× | -3.9% | +12.5% |
| Pharmaron Beijing 3759.HK | Hong Kong | $11.3B | +45% | +24% | 14% | 22.9× | n/a | n/a |
| PharmaEssentia 6446.TW | Taiwan | $15.8B | +118% | +64% | 38% | 39.2× | 29.3% | +94.8% |
| Repligen RGEN | United States | $11.1B | +41% | +14% | 9% | 71.3× | 56.4% | +15.0% |
| Mankind Pharma MANKIND.NS | India | $11.1B | +7% | +13% | 21% | 43.2× | 27.6% | +18.1% |
| Ascendis Pharma A/S ASND | United States | $16.0B | +8% | +128% | 10% | 40.8× | 36.4% | +152.4% |
| Orion ORNAV.HE | Finland | $16.1B | +51% | +34% | 38% | 23.5× | -6.3% | +11.7% |
| Sichuan Biokin Pharmaceutical 688506.SS | China | $16.4B | -3% | +14% | -43% | n/a | n/a | n/a |
| Shionogi & 4507.T | Japan | $16.6B | -6% | +46% | 29% | 10.9× | -0.7% | +11.0% |
| Exelixis EXEL | United States | $17.0B | +44% | +9% | 40% | 18.2× | -3.7% | +18.6% |
| Akeso 9926.HK | Hong Kong | $10.2B | -38% | +42% | -25% | n/a | n/a | n/a |
| Swedish Orphan Biovitrum SOBI.ST | Sweden | $17.6B | +13% | +15% | 30% | 25.5× | -1.1% | +13.1% |